PELI1 exerts pro-tumour effects through dual mechanisms: it facilitates K48-linked ubiquitination of RPS via its FHA domain (destabilising p53 [106]) and mediates degradation of the tumour suppressor INPP5J [107], collectively driving tumour progression. Here, PELI1 is linked to neoplasm.